Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

rials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of Micromet's product candidate
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... The AMA is pleased to share with ... that Alaska Governor Sean Parnell has signed House Bill ... use of Unmanned Aircraft Systems and the continuation of ... that it is, “An Act relating to unmanned aircraft ... aircraft system.” It defines State of Alaska laws regarding ...
(Date:8/21/2014)... 2014 DNA vaccine pioneer Immunomic ... development of JRC-LAMP-vax, an innovative and safe potential treatment ... studies began this month in Hawaii, moving the world ... The Japanese red cedar releases pollen that causes devastating ... Cedar pollen wreaks similar havoc in Colorado, New Mexico ...
(Date:8/21/2014)... August 21, 2014 His Majesty Willem-Alexander, ... , The Court of His Majesty Willem-Alexander, King of ... the Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY ... 3. , The King will take part in the ... scheduled for 11 a.m.-12:20 p.m. and tour the plant. ...
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
Breaking Biology Technology:State of Alaska Signs Unmanned Aircraft Systems Bill 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... March 10 Campbell Alliance, the leading ... industry, today announced that Ashwin Dandekar, Vice President, Brand ... Summit USA on March 30 and 31, 2009 at ... Dr. Dandekar will also present a workshop at EyeForPharma,s ...
... Off-Label Use of Avastin Will Take Market Share ... to a New Report from Decision ResourcesWALTHAM, Mass., ... world,s leading research and advisory firms for pharmaceutical ... percent growth in the age-related macular degeneration (AMD) ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a ... Jeffrey H. Burbank, Chief Executive Officer, will be presenting ... on Monday, March 16, 2009 at the Marriot Copley ... for Monday, March 16th at 4:40 p.m. ET. ...
Cached Biology Technology:Campbell Alliance Brand Management Practice to Present at EyeForPharma's Oncology Summit USA and Oncology Market Access Europe Conference 2Campbell Alliance Brand Management Practice to Present at EyeForPharma's Oncology Summit USA and Oncology Market Access Europe Conference 3Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 3NxStage to Present at the Cowen and Company 29th Annual Healthcare Conference 2
(Date:8/21/2014)... significant reduction in smog-producing toxins in past decade, ... new study shows that while the Greater Toronto ... toxins that contribute to smog, the city continues ... pollution., Smog, which can cause or aggravate health ... is produced by a set of complex photochemical ...
(Date:8/21/2014)... dandruff, eczema and other itchy, flaky maladies in humans ... Hawaiian coral reefs and the extreme environments of arctic ... the scientific journal PLOS Pathogens considers the ... genus Malassezia in light of new insights ... world. , University of Hawai,i at Mānoa scientist Anthony ...
(Date:8/21/2014)... AWI geologist Juliane Mller the Fram Strait is a key ... of this passage between Greenland and Svalbard warm Atlantic water ... the west side cold Arctic water masses and sea ice ... Atlantic. A considerable portion of the Atlantic water cools here ... layers. The circulation of the water caused in this manner ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
... Fifty-nine leading life scientists from Europe and around the ... Organization (EMBO) for their proven excellence in research. Fifty-one ... Europe and neighbouring countries, while eight equally respected scientists ... as Associate Members, bringing the current membership total to ...
... herbicide that is effective at killing broadleaf weeds in ... Illinois and other Midwestern states, may finally have a ... developed a new grape called Improved Chancellor which is ... 1946, 2,4-Dichlorophenoxyacetic or 2, 4-D was introduced. It was ...
... is available in Spanish . An ... the Institute for Research in Biomedicine (IRB Barcelona) and ... (ICIQ, Tarragona), have discovered a substance with the capacity ... certain mutations that promote the appearance of cancer. Giralt, ...
Cached Biology News:EMBO honors 59 leading life scientists 2Herbicide-resistant grape could revitalize Midwest wine industry 2Herbicide-resistant grape could revitalize Midwest wine industry 3Design of a compound that stabilizes the main natural suppressor of tumors 2
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Phospho-FADD (Ser194) Antibody (Human Specific)...
... polyclonal to FANCM ( Abpromise for ... Synthetic peptide derived from within residues ... (Note: the amino acid sequence is ... ab27787 .) Entrez ...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Biology Products: